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The slow-reacting substances (SRS) consist of leukotrienes C, D, and E (LTC, 
-D,  -E) 1 and  are  derived  from  the  lipoxygenase pathway  of arachidonic  acid 
(20:4) metabolism. In examining possible mechanisms for the vasoactive effects 
of SRS  (1-4),  we  found that  cultures  of human  endothelial  cells  release  the 
vasodilatory agent, prostacyclin, on exposure to 10 -9 to 10 -6 M LTC (5). Previous 
reports indicated that several structurally unrelated vasoactive substances such 
as  histamine  (6)  and  bradykinin  (7)  also  stimulate  prostacyclin  synthesis  by 
endothelium. Together these results suggested that the leukotrienes and other 
vasoactive substances may promote vasodilation through a common mechanism. 
To  further examine the specificity of leukotrienes in initiating 20:4  release 
and  the  synthesis of prostacyclin,  we  exposed  human endothelial  cells  to  the 
cysteine-containing leukotrienes,  LTC,  LTD,  and  LTE,  and  to  5(S),  12(R)- 
dihydroxy-eicosa-6,14 cis-8,10 trans tetraenoic acid or LTB. These studies per- 
mitted the demonstration that LTC and LTD promote the release of prostacy- 
clin, but that LTE and LTB were  inactive in stimulating endothelial cell 20:4 
metabolism.  The  additional  finding that endothelial  cells  metabolize  LTC  to 
LTD and LTE suggested one mechanism whereby the vasoactive effects of these 
substances are modulated. 
Materials and Methods 
Materials.  Radiolabeled lipids were purchased from New England Nuclear, Boston, 
MA and included [5,6,8,9,11,12,14,15-SH]20:4  ([SH]20:4) (91.2 Ci/mmol; 1 Ci -- 3.7 × 
101°  Bq),  6-keto-[5,8,9,11,12,14,15-SH(N)PGF~,  (120-180  Ci/mmol),  [5,6,8,9,11- 
12,14,15SH(N)]thromboxane  B2  (100-150  Ci/mmot),  [5,6,8,11,12,I4,15aH(N)]- 
PGF~  (150-180  Ci/mmol),  and  [5,6,8,11,12,14,15"SH(N)]PGE2  (100-200  Ci/mmoi). 
Histamine, glutathione, 3,-glutamyi  transpeptidase (~,-GTPase)  (bovine kidney), leucine 
aminopeptidase, and 3,-glutamyl-p-nitroanilide were obtained from Sigma Chemical Co., 
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St.  Louis, MO. Thrombin was purchased from Ortho Diagnostic Systems, Inc., Rahway, 
NJ and collagenase type II from Worthington Biochemical Corp., Freehold, NJ. L-(ct, 5S)- 
a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125) and L-3,-glutamyl-O-carbox- 
yphenylhydrazide were gifts from Dr. Owen Griffith, Cornell Medical College. 
Culture of Endothelial Cells.  Endothelial cells were harvested from the vein of human 
umbilical cord (8) with collagenase and cultured in medium 199 (M-199) (Gibco Labora- 
tories, Grand Island, NY) containing 20% heat-inactivated human serum (HS) as described 
(5).  All  cells examined were positive for factor VIII antigen as determined by indirect 
immunofluorescence (9).  All experiments were performed with first passage cells grown 
to at least 75% confluency on 35-mm or 60-mm dishes. Endothelial cells were shown to 
remain viable after exposure to each of the agents  used  in  this study  by trypan blue 
exclusion of a representative set of cultures. 
20:4 Metabolism.  The phospholipids of endothelial cells in 35-mm plastic tissue culture 
dishes were labeled overnight with 1.0 ~Ci of [all/20:4 in 1 ml of M-199 containing 20% 
HS. The cells were washed twice with 2 ml of M-199 (no serum), overlaid with fresh M- 
199, and exposed to the appropriate stimulus. Duplicate 50-tzl aliquots of medium were 
removed  and  ~H  content  determined  by  liquid  scintillation  counting  in  Hydrofluor 
(National Diagnostics, Inc., Sommerville, NJ).  Alternatively,  100 #1 aliquots of medium 
were removed at the indicated times, spun in a  microfuge to remove any foating cells, 
and 50 ~tl aliquots of the supernatant were removed for radioactivity determinations. 
At the end of the experiment, the remaining medium was removed. 20:4 metabolites 
were  extracted  by the  method  of Unger  et al.  (10)  as  described  previously (11)  and 
separated by HPLC System I as described below. After removal of the medium, the cells 
were washed twice  with  2  mi of phosphate-buffered saline  (Ca  ++ and  Mg  ÷+ free) and 
scraped into 1 ml of 0.05% Triton X-100. Duplicate 50-~tl aliquots of the cell lysates were 
removed for radioactivity determinations. Protein contents of 100-~! aliquots were mea- 
sured by the method of Lowry et al. (12) with bovine serum albumin as a standard. 
Reverse Phase High Pressure Liquid Chromatography (HPLC).  Media extracts containing 
20:4 metabolites were dried to nil under a stream of nitrogen, and dissolved in 0.4 ml of 
the appropriate HPLC starting buffer. 
HPLC  System  I  (5)  was  used  to  separate  total  20:4  oxygenated  metabolites  and 
individual leukotrienes (LTC, LTD, and LTE). HPLC System I consisted of a 4.6 mm x 
25 cm column of 5-tzm Ultrasphere ODS (Altex Instruments, Woiburn, MA) eluted at 1 
ml/min with (a) 60 ml of methanol/water/acetic acid (65:34.9:0.1,  vol/vol/vol) adjusted 
to pH 5.4  with ammonium hydroxide, followed by (b) 40  ml of methanol/water/acetic 
acid (75:25:0.01,  vol/vol/vol), and then (c) 40 mi of methanol/acetic acid (100:0.01, vol/ 
vol). Column effluents were monitored for absorption at 280 nm with a Kratos Spectroflow 
773  Monitor (Kratos, Inc., Schoeffel Instrument Division, Westwood, NJ).  LTC, LTD, 
and  LTE  were  quantitated  by  their  absorption  at  280  nm,  assuming  an  extinction 
coefficient of 40,000  M -~  • cm  -t  (13).  Where appropriate, the  radiolabel contents of 
column fractions were determined. The elution times of LTC, LTD, and LTE were 19- 
21, 43-45, and 49-51  min, respectively. For identification of individual cyclooxygenase 
products,  the contents of fractions 4-16 from System I were pooled, taken to dryness, 
and redissolved in the starting buffer for System II. 
HPLC System II consisted of a  3.6  mm x  30  cm Waters fatty acid analysis column 
(Waters Associates, Inc. Milford, MA) eluted at 2 ml/min with 50 ml of water/acetonitrile/ 
benzene/acetic acid (76.7:23.0:0.2:0.1,  vol/vol/vol/vol), followed by 20 ml of methanol/ 
acetic acid  (100:0.01,  vol/vol) (5).  Fractions of 2  ml were collected and the  radiolabel 
content 9 f each was determined as described above. The elution times of 20:4 oxygenated 
metabolites on HPLC Systems I and II were determined using commercial radiolabeled 
standards (cyclooxygenase products) or radiolabeled standards prepared in this laboratory 
(lipoxygenase products). 
Preparation of Leukotrienes.  LTC was extracted from culture medium of mouse peri- 
toneal  macrophages prelabeled with  [3H]20:4  stimulated  with  the  maximal phagocytic POLOGE  ET  AL.  1045 
load of unopsonized zymosan (11) (ICN K & K Laboratories Inc., Plainview, NY) or  10 
ug/ml calcium ionophore A23187  (Calbiochem-Behring Corp., La Jolla, CA). [SH]LTC 
was extracted from medium of mouse peritoneal macrophages that were prelabeled with 
[3H]20:4 for 16 h and stimulated as described above. LTD and [3H]LTD were prepared 
by treatment of LTC and [3H]LTC with 3,-GTPase (14) and the reaction was stopped by 
extraction at 4°C. 
LTE was prepared from LTD by a  modification of the procedure of Sok et al. (14). 
Briefly, 3,-GTPase-treated LTC was extracted at 4°C, dried  under nitrogen, and redis- 
solved in 1 ml of 0.05 M Tris, pH 8.5, containing 10 mM MgCI2. The leukotrienes were 
treated with 0.8-1.0 U of leucine aminopeptidase for 30 min at room temperature. The 
reaction  was stopped by extraction at 4°C.  The  leukotrienes  were purified by HPLC 
System I. 
LTC Metabolism.  Endothelial  cell  cultures  were  washed  twice  with  2  ml  of M-199 
without serum, overlaid with  1 ml of fresh, serum-free M-199 or RPMI  1640  medium 
(Gibco Laboratories), and incubated at 37 °C in the indicated concentrations of [SH]LTC. 
Controls consisted of [SH]LTC incubated in M-199 or RPMI 1640 medium in the absence 
of cells.  No conversions of LTC to LTD or LTE were observed in the controls. At the 
specified times,  media were  removed from the  endothelial  cell  cultures  and  controls, 
extracted for 20:4 metabolites, and the leukotrienes separated by HPLC System I. The 
percentage of each leukotriene was determined from the SH content of the appropriate 
fractions. 
Assay of-r-GTPase.  3,-GTPase activity of endothelial cells was measured by a  modifi- 
cation  of the  method  of Szasz  (15).  Briefly, endothelial  cell  lysates were prepared  by 
scraping cells from 60-ram culture dishes  into  100  ~tl of Triton  X-100  (0.5%  wt/vol). 
Control samples contained  100 #1 of Triton X-100 only. Reactions were initiated by the 
addition of 0.9 ml of 0.5 M Tris buffer, pH 8.5, containing 25 mM glycylglycine and 2.5 
mM of L-'y-glutamyl-p-nitroanilide. After vortexing, the mixture was incubated at 37 °C. 
The reactions were stopped on ice and centrifuged to remove cellular debris. Formation 
of the  cleavage product,  p-nitroaniline,  was quantitated  spectrophotometricaily at  405 
nm, assuming an extinction coefficient of 9,900 M -~  • cm  -~ (I 5). Activity is expressed as 
#moles ofp-nitroaniline released per minute. 
In  some  experiments,  the  reaction  mixture  was  added  directly  to  endothelial  cell 
cultures in 60-ram dishes. The Tris buffer was replaced by RPMI  1640 medium (RPMI 
Select-Amide Kit; Gibco Laboratories), pH 7.1,  less glutathione, vitamins, and pH indi- 
cator. The reaction volume was generally 4 ml. At the indicated times, 1-ml aliquots were 
removed to determine the quantity ofp-nitroaniline (above). Controls consisted of reaction 
mixtures incubated in dishes without cells. 
Results 
20:4 Release.  As noted previously, 10 -3 to 10 -6 M  LTC promoted the release 
of 20:4 from endogenous phospholipid stores in endothelial cell cultures (5). Fig. 
1 shows the time course of SH release by endothelial cell cultures prelabeled with 
[3H]20:4  and  exposed  to  various  concentrations  of LTD.  Release  occurred  at 
10 -8 M  LTD and reached maximal levels of 3% of the cell-associated radiolabel 
at  1-4 ×  10  -7 LTD. Similar to the endothelial cell response to an LTC stimulus 
(5), the amount of radiolabel released into the culture medium increased during 
the first  15-30 min of exposure to LTD and leveled off thereafter. 
Fig.  2  compares the release of radiolabel by endothelial  cell cultures exposed 
to  10 -7 M  LTC,  LTD, or LTE. This concentration of LTC (5), as well as LTD, 
elicited maximal release of radiolabel.  Because the amount of release promoted 
by individual  leukotrienes  varied,  their  potency was directly  compared  within 1046  LEUKOTRIENES STIMULATE ENDOTHELIAL PROSTACYCLIN  SYNTHESIS 
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FIGURE  l.  Time  course  of radiolabel  release  by  endothelial cells as  a  function  of LTD 
concentration. Cultures were labeled overnight with [SH]20:4  in M-199 and 20%  HS.  After 
washing with M-199, the cultures were overlaid with M-199 +  the indicated concentration of 
LTD.  Release is expressed as the percent of total cell radiolabel  recovered in  the culture 
medium. At each time point, values are corrected for all counting aliquots removed at previous 
time points. Control cultures were incubated in M-199 in the absence of any stimulus. Values 
are mean +  range (n =  2). 
,01  /*  .= 
2.0  ./~- 
to  20  30  40  50  60 
Minutes 
FIGURE 2.  Time  course  of radiolabel  release by  endothelial  cells  in  response  to  10  -7  M 
leukotrienes  or  no  stimulus  (control).  The  experimental  conditions were  similar  to  those 
described in Fig.  1. Data are expressed as the mean +  range of percent release (n =  2). 
the same experiments.  The percent of radiolabel released in  response  to  the 
LTC challenge was consistently higher than in response to LTD. In this experi- 
ment, 3.8% of the total cell-associated radiolabel was recovered in the medium 
of LTC-treated  cultures  compared  with  2.5%  for  LTD-treated  cultures.  In 
addition, LTC promoted a higher level of release than did LTD at all concen- 
trations  tested  (1  ×  10 -3  to  4  ×  10 -7  M)  (data  not  shown).  In  a  separate 
experiment, the 11-trans isomer of LTC at 10  -7 M caused 3.12 +  0.26% release 
of radiolabel compared with 3.52 +  0.48% with the equivalent concentration of 
LTC. 
In contrast, no release of radiolabel above control levels was observed when 
endothelial cell cultures were exposed to LTE in concentrations of up to 10  -6 M 
(Fig.  3).  LTB  at  10  -6  M  was  also  ineffective in  stimulating  20:4  release  by 
endothelial cells (Fig.  3),  and this concentration of LTB failed to block  20:4 
release by cultures subsequently challenged with 10  -7 M LTC. 
If endothelial cells were challenged with a maximal LTC stimulus (10 -7 M) for 
30 min (n =  5), the response of these cells to a  second such challenge of LTC 
was reduced >90%  compared with the level of radiolabel released by cells  not POLOGE  ET  AL.  1047 
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FIGURE  3.  Time course of radiolabel release by endothelial cells in response to  1 x  10  -6 M 
(A) LTB  (0-60  min), (O)  LTE,  or ((3)  no stimulus. The  experimental conditions are  those 
described in Fig.  1. At 60 min, 1  x  10  -7 M  LTC (arrow) was added to the culture incubated 
in LTB. 
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FIGURE  4.  Time course of radiolabel  release by endothelial cells in response to sequential 
exposures to LTC. Data are expressed as the mean +  range (n =  2). At time 0, cultures were 
challenged with  1  x  10  -7 M  LTC  (x),  1  X  10  -8 M  LTC  (O),  1  X  10  -9 M  LTC  (A),  or no 
stimulus (O).  At 35 min, the cultures indicated by the arrows were given a  second challenge 
ofl  x  10  -~MLTC. 
previously  exposed  to  LTC  (Fig.  4).  However,  endothelial  cells  retained  the 
capacity to respond to multiple challenges of SRS by the release of endogenous 
20:4, provided that the level of the stimulus was submaximal (Fig. 4). After a 30 
min  exposure  to  10 -s  M  LTC  in  serum-free  medium,  additional  release  of 
radiolabel was evident when cultures were challenged with a second dose of 10 -7 1048  LEUKOTRIENES STIMULATE ENDOTHELIAL PROSTACYCLIN SYNTHESIS 
M  LTC. In preliminary experiments, additional release of radiolabel was noted 
when cells exposed to 10  -7 M  LTC were challenged with  1 U/ml of thrombin. 
20:4  Metabolites.  Prostacyclin was  the major 20:4  metabolite synthesized by 
endothelial cells exposed to either LTC or LTD. Fig. 5 shows HPLC separations 
of the radiolabeled products released into the culture medium. The prominent 
peak  eluting  in  fractions  4-16  from  HPLC  System  I  consisted  primarily  of 
cyclooxygenase products. The other major peak in fractions 114-124 contained 
unreacted  20:4.  Separation  of individual  cyclooxygenase products  by  HPLC 
System II  indicated that  the predominant peak of radiolabel  had elution char- 
acteristics of 6-keto PGF~,, the breakdown product of prostacyclin. 
Leukotriene  Metabolism.  The fate of [SH]LTC added to culture medium  was 
assessed by HPLC after a  1 h  exposure to endothelial cells. No uptake of LTC 
by these  cultures  was  evident as  determined  by  the  absence  of ceil-associated 
radiolabel at the end of the experiment. 
The elution profile of the radiolabel extracted from culture medium is shown 
in Fig.  6  along with the profile of radiolabel obtained after a  1 h  incubation of 
[3H]LTC in medium without cells. >97%  of the radiolabel extracted from con- 
trol medium (no cells) eluted in a  single peak as LTC. Two additional peaks of 
radiolabel with elution times corresponding to LTD (44 min) and LTE (49 min) 
were evident after exposure of LTD to cells.  LTC,  LTC, and  LTE accounted 
for 57,  33,  and  10%  of the total radiolabel  recovered, indicating  that  43%  of 
the LTC was metabolized during the  1 h  exposure to endothelial cells. 
Fig. 7 shows the time course of LTC metabolism by endothelial cells. Cultures 
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FIGURE 5.  HPLC elution profiles  of  the [3H]20:4 metaDolites  released  by endothelial  cells in 
response to a 60 min exposure to I  X 10  -7 M LTD or in M-199 (no stimulus). Total 20:4 
metabolites released by ceils exposed to (A) LTD and (B) no stimulus were extracted from 
culture media and separated on HPLC System I. Cyclooxygenase products eluted in 4-16 
min, lipoxygenase products in 17-110 min, and free 20:4 in 110-140  rain. Cyclooxygenase 
products released by (C) cells exposed to LTD and (D) by control cells were pooled separately 
and rechromatographed using HPLC System II. Elution times of radiolabeled standards were: 
6-keto PGF~, 10 rain; and PGE, 24-25 min. POLOGE  ET  AL.  1049 
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FIGURE 6.  Metabolism of LTC  by endothelial cells.  HPLC  System  I  profiles showing the 
fate of [SH]LTC incubated for 1 h. (A) M-199 (no cells) and (B) M-199 plus cells. Radiolabeled 
LTC, LTD, and LTE standards eluted at 20, 44, and 49, respectively. 
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FIGURE 7.  Time course of LTC  metabolism by endothelial cells. Cultures were incubated 
for the indicated times with  t  ×  10  -7  M  LTC.  The culture media were extracted and the 
leukotrienes separated by HPLC System I. The level of each leukotriene was determined from 
the radiolabel content of appropriate peaks in the HPLC elution profiles. 
containing an average of 133  #g of cell protein were incubated with  10  -7  M 
LTC for the indicated times. The rate of LTC disappearance was approximately 
linear for the first 30 rain, and slowed thereafter. Concomitant increases in the 
levels  of LTD  and  LTE  were  evident.  By  120  rain,  63%  of the  LTC  was 
metabolized in this experiment. 1050  LEUKOTRIENES STIMULATE ENDOTHELIAL PROSTACYCLIN SYNTHESIS 
7-GTPase.  ~-GTPase catalyzes the conversion of LTC to LTD (16).  Levels 
of 7-GTPase  were  measured  using  the  chromogenic  substrate  L-~'-glutamyl-p- 
nitroanilide  (15) and Triton X-100-solubilized cell extracts. At pH 8.5, the pH 
optimum of the enzyme (17), the level of 7-GTPase activity was 6.5 +  0.4 ×  10 -7 
U/mg cell protein (n =  2). 
Using  the  same  substrate  we were also able  to  detect  ~-GTPase activity  in 
intact cells maintained in medium (RPMI) at pH 7.1, but only if the transpeptidase 
acceptor glycylglycine was present.  In three experiments, the activity was 4.8 + 
3.5 ×  10 -8 U/mg cell protein. Endothelial cells hydrolyze LTC under these same 
conditions in the absence of an acceptor. Although the activity is 14-fold less in 
whole cells than in Triton X-100 extracts, it is nevertheless sufficient to account 
for the rate of LTC metabolism as calculated from the data in Fig. 7. 
We questioned  whether  inhibitors  of ~,-GTPase also block LTC  metabolism 
by intact endothelial cells. Glutathione inhibited (>80%) the conversion of LTC 
(10 -7 M) to LTD and LTE but only when present in vast molar excess (10 mM) 
to the LTC substrate. Preincubation of cells with  1 mM AT-125, an irreversible 
7-GTPase inhibitor  (18), for  1 h  achieved the same level of inhibition  of LTC 
metabolism as for hydrolysis of~,-glutamyl-p-nitroanilide. However, no significant 
inhibition  of LTC  breakdown  was  noted  with  the  specific  and  reversible  ~- 
GTPase  inhibitor  L-~,-glutamyl-O-carboxyphenylhydrazide  (19),  although  this 
compound (1  mM) blocked (>93%) the hydrolysis of the colorimetric substrate 
by intact cells. 
Histamine.  It  was of interest  to  directly  compare  prostacyclin  synthesis by 
endothelial  cells stimulated  with  LTC  and  a  structurally  unrelated  vasoactive 
agent.  For this  purpose  we chose histamine,  which  has been  reported  (20)  to 
stimulate the release of prostacyclin by endothelium. At 10 -7 M, a concentration 
at which both LTC and LTD induced maximal release of 20:4 from endothelial 
cells, histamine had no effect. Release of radiolabel from endothelial cells above 
basal levels was evident at  10 -6 M histamine; however, maximal  levels of release 
required 5 ×  10 -6 M histamine.  HPLC profiles of the 20:4 metabolites released 
by histamine-challenged  cells were similar to those shown in Fig.  5.  Consistent 
with the kinetics of prostacyclin synthesis reported by others (20), the histamine- 
mediated 20:4 release plateaued in  10 min and was more rapid than the  15-30 
min release promoted by LTC. In this regard, the histamine-mediated response 
more closely paralleled that elicited by thrombin (5) than the leukotrienes. 
Discussion 
LTC,  11-trans  LTC, and  LTD, but not LTE and  LTB, promote the release 
of radiolabel by cultured human endothelial cells prelabeled with [~H]20:4. The 
radiolabel  recovered  in  the  culture  medium  was primarily  6-keto  PGFI~,  the 
breakdown  product  of  prostacyclin.  Direct  comparisons  of  the  leukotrienes 
indicated that LTC and  11-trans LTC, on a molar basis, were more effective in 
eliciting prostacyclin synthesis than  LTD.  LTE and  LTB within the same con- 
centration range (10  -9 to  10 -6 M) as LTC and LTD failed to elicit prostacyclin 
synthesis  above  basal  levels.  The  rank  order  of the  leukotrienes  in  eliciting POLOGE ET AL.  1051 
prostacyclin release by cultured human endothelium is: LTC ~  11-trans LTC > 
LTD >>> LTE =  LTB. 
The relative effectiveness of the leukotrienes in promoting prostacyclin syn- 
thesis indicated that specific structural features of the leukotriene molecule are 
essential for stimulation of prostacyclin synthesis by cultured endothelium. Re- 
moval of the glutamyl residue from  LTC  caused  ~50%  loss  in  activity, and 
removal of the glycyl moiety (conversion of LTD to LTE) rendered the molecule 
inactive. The necessity of the peptide backbone was further indicated by the fact 
that LTB was also inactive as a stimulus for prostacyclin synthesis by endothelial 
cells. However, a change in the fatty acid moiety of LTC to the 11-trans isomer 
had little effect on leukotriene-stimulated prostacyclin synthesis. It remains to be 
determined whether receptors for LTC  and or LTD  exist on  the surface of 
endothelial cells.  However, the evident requirement for structural features of 
the  peptide  backbone  and  the  low  concentrations  of  these  lipid  mediators 
required for initiation of prostacyclin formation suggest this possibility. 
The potency of leukotrienes in causing prostacyclin synthesis was compared 
with that of histamine, an important vasoactive agent. It is well established that 
histamine promotes prostacyclin synthesis by cultured endothelial cells, and it is 
likely that this effect is  mediated via an  H1  receptor (20).  As with  LTC and 
LTD, histamine-induced 20:4 release is dose dependent; however, higher con- 
centrations (1-5  tzM) are required to promote levels of prostacyclin synthesis 
comparable to those elicited by 0.1 ttM LTC. The kinetics of histamine-mediated 
prostacyclin synthesis are more rapid  than  in  leukotriene-stimulated cultures, 
with a time course of <10 min. 
Endothelial cell cultures metabolized LTC to LTD and LTE at concentrations 
(10  -7 M) that promote prostacyclin synthesis. Thus, these cells have the capacity 
to inactivate the vasoactive leukotrienes. This may be one mechanism for con- 
trolling the level of prostacyclin formation and may explain the transient effects 
of these lipid mediators on the vasculature. However, the rate of LTC metabolism 
by these cells is slow compared with the rate of prostacyclin synthesis. It is likely 
that other mechanisms are also involved in either inhibiting prostacyclin synthesis 
or the binding of leukotrienes to endothelium. 
Anderson et al. (16) have shown that purified 3'-GTPase catalyzes the conver- 
sion of LTC  into  LTD.  Recently, this  enzyme was localized by cytochemical 
techniques to endothelial cell plasma membranes in rat hyperplastic liver (21). 
Levels of 3,-GTPase activity in intact endothelial cells and Triton X-100 extracts 
of endothelial cells were sufficient to account for LTC metabolism. 
LTC metabolism in intact endothelial cells was blocked by AT-125, an irre- 
versible 3'-GTPase inhibitor (19), and also by glutathione when in considerable 
molar  excess  to  the  substrate.  Hammarstrom  (22)  previously  reported  that 
glutathione inhibits the formation of LTD  from LTC by partially purified 3'- 
GTPase from swine kidney. However, in intact endothelial cells, no inhibition 
was seen with the specific inhibitor of 3,-GTPase, GCPH (18), at a 400-fold molar 
excess over the LTC concentration. The explanation for this discrepancy remains 
to be determined. 
It is interesting that all three cysteinyl-containing ieukotrienes induce plasma 1052  LEUKOTRIENES  STIMULATE  ENDOTHELIAL  PROSTACYCLIN SYNTHESIS 
transudation from microvasculature (3,  23),  but  only LTC and  LTD trigger 
prostacyclin  formation  by  endothelial  cells.  Prostacyclin  induces  dilation  in 
postcapillary venules, but is not known to lead to plasma transudation. Together 
these observations suggest that vascular dilation and permeability may not be 
causally related. A second factor or mechanism may control vessel permeability 
and the quantity of plasma exudate (24). 
Summary 
Cultured endothelial cells  from human umbilical cord labeled with [3H]20:4 
release radiolabel when exposed to leukotrienes C  or  D (LTC or  LTD).  The 
major radiolabeled 20:4 metabolite recovered in the culture medium was pros- 
tacyclin. Both ieukotrienes produced a dose-dependent synthesis of prostacyclin, 
with a maximal response at 10  -7 M leukotriene. LTC promoted a twofold greater 
response than did LTD at all concentrations tested (10 -9 to 10  -7 M). In contrast, 
no release of radiolabel above basal levels was evident with a challenge of LTE 
or LTB at the same concentrations. 
Endothelial cells metabolize ~40-50% of exogenously supplied LTC to LTD 
and LTE in 60 rain. Levels of a-glutamyltranspeptidase (3,-GTPase),  the ectoen- 
zyme reported to convert LTC to LTD, were detected in intact endothelial cells 
with the chromogenic substrate L-3,-glutamyl-p-nitroanilide at levels sufficient to 
account for the observed rate of LTC metabolism. High concentrations of the 
7-GTPase inhibitors, glutathione and AT-125, blocked the metabolism of LTC 
by  endothelium.  These  results  suggest  that  degradation  of leukotrienes  by 
endothelium may be one mechanism for inactivation of these lipid mediators. 
Received for publication  6June 1984. 
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